Eli Lilly Follows Novo in Slashing China Obesity Drug Price
Eli Lilly & Co slashed the price of its blockbuster weight-loss and diabetes drug Mounjaro in China, intensifying competition with Novo Nordisk A/S and local rivals.
By Amber Tong · Bloomberg
Eli Lilly & Co slashed the price of its blockbuster weight-loss and diabetes drug Mounjaro in China, intensifying competition with Novo Nordisk A/S and local rivals.